Cencora, Inc. (COR)
Cencora (COR) Q4 Earnings and Revenues Surpass Estimates
Cencora (COR) came out with quarterly earnings of $3.84 per share, beating the Zacks Consensus Estimate of $3.79 per share. This compares to earnings of $3.34 per share a year ago.
Drug Distributor Cencora to Invest $1 Billion in U.S. Supply Chain
The company will open two new distribution centers and expand a third as demand surges for GLP-1s and other refrigerated medications.
Countdown to Cencora (COR) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Cencora (COR) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Cencora (COR) Earnings Expected to Grow: Should You Buy?
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cencora (COR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cencora, Inc. (COR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Cencora, Inc. (NYSE:COR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants James Cleary - Executive VP & CFO Bennett Murphy - Senior VP, Head of Investor Relations & Treasury Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Good afternoon, everyone. Welcome to Day 3 of the Morgan Stanley Healthcare Conference.
Here's Why Cencora (COR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year?
Here is how Climb Bio, Inc. (CLYM) and Cencora (COR) have performed compared to their sector so far this year.
Why Cencora (COR) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap
Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results should fade in the coming quarters. The valuation remains elevated at 17.9x forward P/E, well above the 5-year average, making the risk/reward unattractive at current levels. Key risks include heavy revenue exposure to Walgreens Boots Alliance, which faces solvency issues and plans to sell its COR stake.
3 Reasons Growth Investors Will Love Cencora (COR)
Cencora (COR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
